Some medicinal products for human use are authorised subject to additional monitoring for reasons of their specific safety profile. Pursuant to Article 23 of Regulation (EC) No 726/2004 this includes medicinal products with a new active substance, biological medicinal products and products for which post-authorisation data are required.
Recital 1, Commission Implementing Regulation (EU) No 198/2013 of 7 March 2013 on the selection of…
In forcesince 7 Mar 2013